Skip to main content
AACR Open Access logoLink to AACR Open Access
. 2022 Sep 15;28(18):4158. doi: 10.1158/1078-0432.CCR-22-2320

Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K Abraham, Douglas C Wilson, Julia F Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A Altura, Corinne Maurice-Dror
PMCID: PMC9475239  PMID: 36106403

In the original version of this article (1), the Spearman correlations were correct in the text and incorrect in Fig. 4. The figure has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.

Reference

  • 1. Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, et al. First-in-class anti-immunoglobulin–like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors. Clin Cancer Res 2022;28:57–70. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cancer Research are provided here courtesy of American Association for Cancer Research

RESOURCES